(Q40083245)

17 September 2017

1 reference

title

beta Adrenergic blocking drugs (English)

1 reference

17 September 2017

Beta adrenergic blocking drugs (English)

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

6 August 2023

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

6 August 2023

author name string

B. N. Prichard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6107938

6 August 2023

C. W. Owens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6107938

6 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6107938

6 August 2023

publication date

1 January 1980

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0163725880900698?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

https://api.elsevier.com/content/article/PII:0163725880900698?httpAccept=text/plain

6 August 2023

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacology & Therapeutics

6 August 2023

published in

1 reference

17 September 2017

11

1 reference

17 September 2017

1

1 reference

17 September 2017

109-139

1 reference

A study of the mechanism of the hemodynamic effects of hydralazine in man

17 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Inhibitory effect of propranolol on the vasoconstrictor response to sympathetic nerve stimulation

6 August 2023

2

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Possible role of a beta-adrenoceptor in the regulation of noradrenaline release by nerve stimulation through a positive feed-back mechanism

6 August 2023

4

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators

6 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Oxygen Affinity and Electrolyte Distribution of Human Blood: Changes Induced by Propranolol

6 August 2023

6

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Letter: Reduction of sudden Deaths after myocardial infarction

6 August 2023

7

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Mechanism of hypotensive effect during betaadrenergic blockade in hypertensive patients.

6 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Untoward effects associated with practolol: demonstration of antibody binding to epithelial tissue

6 August 2023

11

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Evaluation of Long-Term Use of Propranolol in Angina Pectoris

6 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels

6 August 2023

13

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Human pharmacokinetics of sotalol.

6 August 2023

15

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

THE EFFECTS OF SYMPATHECTOMY ON THE ELECTROCARDIOGRAM AND EFFORT TOLERANCE IN ANGINA PECTORIS.

6 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Adrenergic neuron blocking properties of (plus or minus)-propranolol and (plus)-propranolol

6 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Atenolol and chlorthalidone in combination for hypertension

6 August 2023

19

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Alpha and beta adrenergic blockade in hypertension.

6 August 2023

20

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison between alprenolol and chlorthalidone as antihypertensive agents

6 August 2023

21

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison between metoprolol and propranolol as antihypertensive agents. A double-blind cross-over study

6 August 2023

22

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment

6 August 2023

23

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparative study of metoprolol and alpha-methyldopa in untreated essential hypertension

6 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function

6 August 2023

27

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparative investigation of the respiratory and cardiovascular effect of mepindolol, propranolol and pindolol in asthmatic patients

6 August 2023

28

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Letter: Paradoxical effect of pindolol

6 August 2023

31

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of Renal Beta- and Alpha-Adrenergic Stimulation on Proximal Sodium Reabsorption in Dogs

6 August 2023

32

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hypertension complicating treatment with beta-adrenergic blocking drugs

6 August 2023

33

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacokinetics of practolol in renal failure

6 August 2023

35

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Acute effects of varying doses of propranolol upon oxygen haemoglobin affinity in man.

6 August 2023

37

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Oxygen Affinity in Red Cells: Inability to Show Membrane-Bound 2,3-Diphosphoglycerate

6 August 2023

38

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol

6 August 2023

39

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

β-Adrenergic Blockade in Diuretic-Treated Patients with Essential Hypertension

6 August 2023

40

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension

6 August 2023

41

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Timolol: a preliminary report of its pharmacological properties and therapeutic efficacy in angina and hypertension

6 August 2023

42

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol)

6 August 2023

43

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertension

6 August 2023

46

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

6 August 2023

47

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

6 August 2023

Aggression and atheroma.

48

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate.

6 August 2023

49

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride, in essential hypertension

6 August 2023

51

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients

6 August 2023

52

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Double-blind factorial trial

6 August 2023

53

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats

6 August 2023

55

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Combined Propranolol and Digoxin Therapy in Angina Pectoris

6 August 2023

56

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension

6 August 2023

58

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Labetalol in resistant hypertension

6 August 2023

61

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment

6 August 2023

62

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The Transient Anti-Hypertensive Effect of Phentolamine in Patients Receiving Beta-Blocker Treatment

6 August 2023

63

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Cardiovascular effects of beta-adrenoreceptor blocking agents after intracerebroventricular administration in conscious normotensive cats.

6 August 2023

65

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Metabolic consequences of atenolol and propranolol in treatment of essential hypertension

6 August 2023

66

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effects of atenolol and propranolol upon lipolysis

6 August 2023

67

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics

6 August 2023

68

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

6 August 2023

Beta-blockers and asthma

69

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Letter: Beta blocker and blood viscosity

6 August 2023

73

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension

6 August 2023

74

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Central hypotensive effect of propranolol

6 August 2023

75

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Two antihypertensive regimens in family practice. Sotalol and methyldopa compared

6 August 2023

76

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

6 August 2023

77

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity

6 August 2023

78

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol

6 August 2023

79

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Haemodynamic effects of beta-receptor blocking agents and digitalis in ischaemic coronary heart disease with angina pectoris

6 August 2023

80

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Inhibition of the carotid sinus reflex by the chronic administration of propranolol

6 August 2023

81

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Standardized stress and hypertension: comparison of effect of propranolol and methyldopa

6 August 2023

82

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacodynamics of practolol in chronic renal failure.

6 August 2023

83

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Glucose Tolerance and Insulin Release in Hypertensive Patients Treated with the Cardioselective β-Receptor Blocking Agent Metoprolol

6 August 2023

84

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol for the treatment of hypertension in pregnancy

6 August 2023

85

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Systemic circulatory response to stress of simulated flight and to physical exercise before and after propranolol blockade

6 August 2023

86

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

β-Adrenoreceptor-Blocking Agents and Lipid Metabolism

6 August 2023

87

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease

6 August 2023

88

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Decreased renal plasma flow during propranolol treatment in essential hypertension

6 August 2023

90

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Cutaneous and ocular reactions to practolol.

6 August 2023

91

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pindolol in hypertension: a double-blind trial

6 August 2023

92

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of beta-adrenoreceptive antagonists on the morbidity and mortality in cardiovascular disease

6 August 2023

94

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Reduction in the rise of systolic blood pressure during human coitus by the beta-adrenergic blocking agent, propranolol

6 August 2023

97

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Oxprenolol and hydrallazine in the treatment of hypertension

6 August 2023

99

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties

6 August 2023

100

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Noninvasive assessment of clinical response to oral propranolol therapy

6 August 2023

101

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Reversal of Abnormal Platelet Aggregability and Change in Exercise Tolerance in Patients with Angina Pectoris Following Oral Propranolol

6 August 2023

102

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The paradox of beta-adrenergic blockade in hypertension

6 August 2023

103

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of aptin, a beta-adrenergic blocking agent, in arterial hypertension

6 August 2023

104

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Centrally induced hypotensive effects of β-adrenergic blocking drugs

6 August 2023

106

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

A Comparative Study of the Effects of Oxprenolol Versus Propranolol in Essential Hypertension

6 August 2023

107

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacokinetics of dextro-, laevo- and racemic propranolol in man.

6 August 2023

109

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Acute management of severe hypertension with oral labetalol

6 August 2023

110

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Assessment of proximal tubular sodium reabsorption during water diuresis in patients with heart disease

6 August 2023

112

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in the therapy of angina pectoris

6 August 2023

113

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.

6 August 2023

114

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of β-Adrenoreceptor Blocking Drugs on Plasma Volume, Renin and Aldosterone as Components of Their Antihypertensive Action

6 August 2023

115

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of beta-adrenergic receptor blocking drugs on cerebral blood flow

6 August 2023

117

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antihypertensive action of propranolol in man: Lack of evidence for a neural depressive effect

6 August 2023

118

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacokinetics of pindolol in man.

6 August 2023

119

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Sudden coronary death: The occurrence of platelet aggregates in the epicardial arteries of man

6 August 2023

120

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hemodynamic and therapeutic effects of guancydine in hypertension

6 August 2023

121

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled study of atenolol in treatment of hypertension

6 August 2023

123

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled trial of acebutolol in hypertension

6 August 2023

124

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Long term treatment of moderate hypertension with the beta1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse rate under basal conditions

6 August 2023

125

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise

6 August 2023

126

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Twice-daily propranolol treatment for hypertension

6 August 2023

127

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Treatment of hypertension with propranolol and hydralazine

6 August 2023

128

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Twice-daily pindolol and alprenolol in essential hypertension of moderate severity

6 August 2023

130

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Atenolol and three nonselective β-blockers in hypertension

6 August 2023

131

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients

6 August 2023

132

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hypoglycaemia after propranolol in children

6 August 2023

133

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Ineffectiveness of propranolol in hypertensive Jamaicans

6 August 2023

134

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension

6 August 2023

135

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of beta adrenergic blockade on plasma catecholamines in exercise.

6 August 2023

137

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Clinical Pharmacokinetics of β-Adrenoreceptor Blocking Drugs

6 August 2023

139

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of Beta-Adrenergic Blockade on Plasma Volume in Human Subjects

6 August 2023

140

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in the treatment of hypertension

6 August 2023

141

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Central Hypotensive Activity of dl- and d-Propranolol

6 August 2023

142

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Vasodilators in the treatment of hypertension

6 August 2023

143

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

A new look at the treatment of severe hypertension

6 August 2023

144

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Central effect of beta adrenergic blocking agents on arterial blood pressure

6 August 2023

145

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Baroreflex sensitivity in hypertension during beta-adrenergic blockade

6 August 2023

148

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of propranolol on mortality in patients with angina

6 August 2023

149

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Use of labetalol and methyldopa in pregnancy-induced hypertension

6 August 2023

150

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Selective and Non-Selective Beta-Blockade in Renin Release

6 August 2023

151

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of pindolol on plasma renin activity and blood pressure in hypertensive patients

6 August 2023

152

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled trial of oxprenolol and practolol in hypertension.

6 August 2023

154

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol

6 August 2023

157

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effects of beta-adrenoceptor blockade on renin, angiotensin, aldosterone and catecholamines at rest and during exercise

6 August 2023

158

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

A comparison of timolol and propranolol in essential hypertension

6 August 2023

159

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Indications for beta-adrenoceptor blocking drugs in hypertension

6 August 2023

160

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma Norepinephrine Levels in Essential Hypertension

6 August 2023

161

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hemodynamic Long-term Effects of Timolol at Rest and during Exercise in Essential Hypertension

6 August 2023

162

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension

6 August 2023

163

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Alprenolol treatment of angina pectoris

6 August 2023

165

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction

6 August 2023

166

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension

6 August 2023

167

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension

6 August 2023

168

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Raynaud's phenomenon as side effect of beta-blockers in hypertension

6 August 2023

169

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

beta-Adrenoceptor antagonists and respiratory function

6 August 2023

171

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma binding and the affinity of propranolol for a beta receptor in man

6 August 2023

172

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1)

6 August 2023

174

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of chronic adrenergic receptor blockade on plasma renin activity in man

6 August 2023

175

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-adrenergic receptor blocking drugs, hypertension and plasma renin

6 August 2023

179

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study

6 August 2023

181

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man.

6 August 2023

183

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients

6 August 2023

184

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Acute and Long-Term Salt Depletion and β-blockade: Plasma Renin Activity Response and its Relation to Blood Pressure Reduction in Long-Term Treatment

6 August 2023

185

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol

6 August 2023

186

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Mechanism of Increased Sodium Reabsorption during Propranolol Administration

6 August 2023

187

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of Beta Adrenergic Blocking Agents (Alprenolol and Propranolol) in Essential Hypertension

6 August 2023

188

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work

6 August 2023

189

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of mental arithmetic in normotensive and hypertensive subjects, and its modification by beta-adrenergic receptor blockade

6 August 2023

190

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparative studies on central factors contributing to the hypotensive action of propranolol, alprenolol, and their enantiomers.

6 August 2023

191

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Studies of cardioselectivity and partial agonist activity in beta- adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise

6 August 2023

192

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacokinetics of unlabelled and14C-labelled pindolol in uraemia

6 August 2023

193

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Oxygen Affinity in Red Cells: Changes Induced in vivo by Propranolol

6 August 2023

194

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Albumin transcapillary escape rate and plasma volume during long-term beta-adrenergic blockade in essential hypertension.

6 August 2023

195

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of propranolol in mild hypertension

6 August 2023

197

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Trial of combination of guanethidine and oxprenolol in hypertension

6 August 2023

198

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings

6 August 2023

199

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy

6 August 2023

200

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction

6 August 2023

202

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine

6 August 2023

203

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Atenolol and bendrofluazide in hypertension

6 August 2023

204

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Altered renin release and propranolol potentiation of vasodilatory drug hypotension

6 August 2023

205

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Minoxidil--an alternative to nephrectomy for refractory hypertension

6 August 2023

206

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Additive Effect of Beta-Adrenergic Blockers in Combination with Vasodilators in Lowering Blood Pressure

6 August 2023

207

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of autonomic blockade on the baroreflex in man at rest and during exercise.

6 August 2023

208

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris

6 August 2023

209

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Sympathetic nervous function and renin activity in hypertensives on long term drug treatment with propranolol, methyldopa or bendrofluazide

6 August 2023

210

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

HYPOTENSIVE ACTION OF PRONETHALOL.

6 August 2023

211

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-adrenergic receptor blocking drugs in angina pectoris

6 August 2023

213

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The combined effect of propranolol with bethanidine or methyldopa in hypertension

6 August 2023

214

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future

6 August 2023

215

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Labetalol in long-term treatment of hypertension

6 August 2023

217

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

6 August 2023

221

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in hypertension

6 August 2023

222

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Treatment of Hypertension with Propranolol

6 August 2023

223

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise

6 August 2023

224

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta receptor antagonism in hypertension; comparison with the effect of adrenergic neurone inhibition on cardiovascular responses

6 August 2023

225

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium

6 August 2023

226

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Haemodynamic studies in hypertensive patients treated by oral propranolol

6 August 2023

227

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled comparison of labetalol and propranolol in the management of severe hypertension

6 August 2023

228

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Systemic lupus erythematosus syndrome induced by practolol.

6 August 2023

229

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Metabolism of Atenolol in Man

6 August 2023

230

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled trial of propranolol in intermittent claudication

6 August 2023

231

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma noradrenaline and hypertension

6 August 2023

232

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-blockers: once or three times a day?

6 August 2023

233

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparative beta-blocking activities and effects on sodium excretion of sotalol and propranolol

6 August 2023

234

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in hypertension

6 August 2023

235

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacological effects of labetalol in man

6 August 2023

236

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of propranolol on elevated arterial blood pressure

6 August 2023

237

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Intermittent claudication complicating beta-blockade

6 August 2023

239

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide

6 August 2023

240

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Clinical Pharmacokinetics of Propranolol

6 August 2023

241

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment

6 August 2023

242

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Altered hemoglobin-oxygen affinity with long-term propranolol therapy in patients with coronary artery disease

6 August 2023

245

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma Volume and Extracellular Fluid Volume during Long-Term Treatment with Propranolol in Essential Hypertension

6 August 2023

246

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma propranolol levels in adults With observations in four children

6 August 2023

251

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The disposition of propranolol. I. Elimination during oral absorption in man

6 August 2023

252

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease

6 August 2023

253

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hydralazine and beta-adrenergic blockade in the treatment of hypertension

6 August 2023

254

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antihypertensive and β-adrenoceptor antagonist action of timolol

6 August 2023

255

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-adrenergic receptor blocking drugs in hypertension.

6 August 2023

256

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effects of oxprenolol (Trasicor, Ciba 39089-Ba) on patterns of urinary sodium excretion in man

6 August 2023

257

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Unwanted effects of propranolol.

6 August 2023

258

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Cardiovascular responses to carotid and vertebral artery infusions of propranolol

6 August 2023

259

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Dual Adrenoceptor-mediated Control of Noradrenaline Secretion from Human Vasoconstrictor Nerves: Facilitation by β-receptors and Inhibition by α-receptors

6 August 2023

261

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Prazosin: Preliminary Report and Comparative Studies with Other Antihypertensive Agents

6 August 2023

262

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-blockers and plasma renin activity in hypertension.

6 August 2023

263

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure

6 August 2023

264

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Suppression by oxprenolol of adrenergic response to stress.

6 August 2023

265

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Electrocardiogram, plasma catecholamines and lipids, and their modification by oxyprenolol when speaking before an audience.

6 August 2023

266

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effects of propranolol on baroreflex sensitivity in borderline hypertension

6 August 2023

268

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations

6 August 2023

269

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Plasma volume changes with long-term beta-adrenergic blockade

6 August 2023

271

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hypotension after oral propranolol

6 August 2023

273

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in hypertension

6 August 2023

276

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of adrenergic beta-receptor antagonists in angina pectoris.

6 August 2023

277

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Pharmacodynamics of Propranolol in Renal Failure

6 August 2023

278

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antihypertensive therapy with alprenolol, a beta-adrenergic receptor antagonist

6 August 2023

279

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol

6 August 2023

280

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Immediate hemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man

6 August 2023

282

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of prolonged beta-receptor blockade on dry weight and electrophysiological responses of rabbit hearts.

6 August 2023

284

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Morphometric changes in rabbit ventricular myocardium produced by long-term beta-adrenoceptor blockade

6 August 2023

285

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Reduced β-adrenoceptor sensitivity in the elderly

6 August 2023

287

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate)

6 August 2023

288

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Hypotensive action of propranolol

6 August 2023

289

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Practolol treatment in asthmatics

6 August 2023

293

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Letter: Paradoxical effect of pindolol

6 August 2023

295

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The predictable relationship between plasma levels and dose during chronic propranolol therapy

6 August 2023

296

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Atenolol, methyldopa, and chlorthalidone in moderate hypertension

6 August 2023

297

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effects of propranolol on cholesterol-induced atheromatous lesions

6 August 2023

298

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide

6 August 2023

299

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension

6 August 2023

300

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

6 August 2023

301

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Beta-blockers and plasma triglycerides

6 August 2023

302

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Multivariate Analysis of Risk Factors for Coronary Heart Disease

6 August 2023

303

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results

6 August 2023

304

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Antinuclear antibodies in patients receiving non-practolol beta-blockers

6 August 2023

305

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased

6 August 2023

306

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Atenolol and methyldopa in the treatment of hypertension

6 August 2023

307

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Adrenergic receptor mediation of renin secretion.

6 August 2023

308

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol-induced hypoglycaemia and myocardial infarction

6 August 2023

310

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Untoward effects associated with practolol administration: oculomucocutaneous syndrome

6 August 2023

311

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Age-associated decrease in ventricular response to haemodynamic stress during beta-adrenergic blockade

6 August 2023

312

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

The clinical pharmacology of hypotensive vasodilator drugs

6 August 2023

313

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade

6 August 2023

314

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Treatment of hypertension with propranol

6 August 2023

315

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Controlled trial of propranolol in hypertension

6 August 2023

316

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison of propranolol and atenolol in hypertension

6 August 2023

317

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Propranolol in hypertension: a study of long-term therapy, 1964-1970

6 August 2023

319

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

Comparison Between the Acute Hemodynamic Effects and Brain Penetration of Atenolol and Metoprolol

6 August 2023

322

1 reference

https://api.crossref.org/works/10.1016/0163-7258(80)90069-8

6 August 2023

Identifiers

1 reference

17 September 2017

1 reference